AusBioInvest presentation
Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is pleased to announce that its CEO and MD, Dr Michael Baker, will today present at Australia’s premier life science investment conference, AusBioInvest.
Dr Baker will present an overview of Arovella’s CAR-iNKT cell therapy platform and how it may provide important advantages over existing CAR-T cell therapies. He will also present the potential of the platform to be applied to both blood cancers and solid tumours.
